Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
45,497
archived clinical trials in
Breast Cancer

Measurements of Breast Tissue Optical Properties
Measurements of Breast Tissue Optical Properties
Status: Enrolling
Updated:  1/26/2018
Chao Family Comprehensive Cancer Center, UCIMC
mi
from
Orange, CA
Measurements of Breast Tissue Optical Properties
Measurements of Breast Tissue Optical Properties
Status: Enrolling
Updated: 1/26/2018
Chao Family Comprehensive Cancer Center, UCIMC
mi
from
Orange, CA
Click here to add this to my saved trials
Adherence Rate of Monthly Bubble Package Among Patients Prescribed Adjuvant Endocrine Therapy in Breast Cancer Survivors
Estimating the Adherence Rate of a Monthly Bubble Package Among Patients Prescribed Adjuvant Endocrine Therapy in Breast Cancer Survivors
Status: Enrolling
Updated:  1/29/2018
James Graham Brown Cancer Center, University of Louisville
mi
from
Louisville, KY
Adherence Rate of Monthly Bubble Package Among Patients Prescribed Adjuvant Endocrine Therapy in Breast Cancer Survivors
Estimating the Adherence Rate of a Monthly Bubble Package Among Patients Prescribed Adjuvant Endocrine Therapy in Breast Cancer Survivors
Status: Enrolling
Updated: 1/29/2018
James Graham Brown Cancer Center, University of Louisville
mi
from
Louisville, KY
Click here to add this to my saved trials
Computed Radiography (CR) Data Collection for Mammography Computer Aided Detection (CAD)
Computed Radiography (CR) Data Collection for Mammography Computer Aided Detection (CAD)
Status: Enrolling
Updated:  1/29/2018
Breast Health Center, University of California Irvine Medical Center
mi
from
Orange, CA
Computed Radiography (CR) Data Collection for Mammography Computer Aided Detection (CAD)
Computed Radiography (CR) Data Collection for Mammography Computer Aided Detection (CAD)
Status: Enrolling
Updated: 1/29/2018
Breast Health Center, University of California Irvine Medical Center
mi
from
Orange, CA
Click here to add this to my saved trials
Adjuvant Paclitaxel and Trastuzumab for Node-Negative HER2-Positive Breast Cancer
A Phase II Trial of Adjuvant Paclitaxel and Trastuzumab for Node-Negative HER2-Positive Breast Cancer
Status: Enrolling
Updated:  1/30/2018
University of California at San Francisco
mi
from
San Francisco, CA
Adjuvant Paclitaxel and Trastuzumab for Node-Negative HER2-Positive Breast Cancer
A Phase II Trial of Adjuvant Paclitaxel and Trastuzumab for Node-Negative HER2-Positive Breast Cancer
Status: Enrolling
Updated: 1/30/2018
University of California at San Francisco
mi
from
San Francisco, CA
Click here to add this to my saved trials
Adjuvant Paclitaxel and Trastuzumab for Node-Negative HER2-Positive Breast Cancer
A Phase II Trial of Adjuvant Paclitaxel and Trastuzumab for Node-Negative HER2-Positive Breast Cancer
Status: Enrolling
Updated:  1/30/2018
Loyola University Medical Center
mi
from
Maywood, IL
Adjuvant Paclitaxel and Trastuzumab for Node-Negative HER2-Positive Breast Cancer
A Phase II Trial of Adjuvant Paclitaxel and Trastuzumab for Node-Negative HER2-Positive Breast Cancer
Status: Enrolling
Updated: 1/30/2018
Loyola University Medical Center
mi
from
Maywood, IL
Click here to add this to my saved trials
Adjuvant Paclitaxel and Trastuzumab for Node-Negative HER2-Positive Breast Cancer
A Phase II Trial of Adjuvant Paclitaxel and Trastuzumab for Node-Negative HER2-Positive Breast Cancer
Status: Enrolling
Updated:  1/30/2018
Indiana University
mi
from
Indianapolis, IN
Adjuvant Paclitaxel and Trastuzumab for Node-Negative HER2-Positive Breast Cancer
A Phase II Trial of Adjuvant Paclitaxel and Trastuzumab for Node-Negative HER2-Positive Breast Cancer
Status: Enrolling
Updated: 1/30/2018
Indiana University
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Adjuvant Paclitaxel and Trastuzumab for Node-Negative HER2-Positive Breast Cancer
A Phase II Trial of Adjuvant Paclitaxel and Trastuzumab for Node-Negative HER2-Positive Breast Cancer
Status: Enrolling
Updated:  1/30/2018
John Hopkins University
mi
from
Baltimore, MD
Adjuvant Paclitaxel and Trastuzumab for Node-Negative HER2-Positive Breast Cancer
A Phase II Trial of Adjuvant Paclitaxel and Trastuzumab for Node-Negative HER2-Positive Breast Cancer
Status: Enrolling
Updated: 1/30/2018
John Hopkins University
mi
from
Baltimore, MD
Click here to add this to my saved trials
Adjuvant Paclitaxel and Trastuzumab for Node-Negative HER2-Positive Breast Cancer
A Phase II Trial of Adjuvant Paclitaxel and Trastuzumab for Node-Negative HER2-Positive Breast Cancer
Status: Enrolling
Updated:  1/30/2018
Massachusetts General Hospital
mi
from
Boston, MA
Adjuvant Paclitaxel and Trastuzumab for Node-Negative HER2-Positive Breast Cancer
A Phase II Trial of Adjuvant Paclitaxel and Trastuzumab for Node-Negative HER2-Positive Breast Cancer
Status: Enrolling
Updated: 1/30/2018
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Adjuvant Paclitaxel and Trastuzumab for Node-Negative HER2-Positive Breast Cancer
A Phase II Trial of Adjuvant Paclitaxel and Trastuzumab for Node-Negative HER2-Positive Breast Cancer
Status: Enrolling
Updated:  1/30/2018
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Adjuvant Paclitaxel and Trastuzumab for Node-Negative HER2-Positive Breast Cancer
A Phase II Trial of Adjuvant Paclitaxel and Trastuzumab for Node-Negative HER2-Positive Breast Cancer
Status: Enrolling
Updated: 1/30/2018
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Click here to add this to my saved trials
Adjuvant Paclitaxel and Trastuzumab for Node-Negative HER2-Positive Breast Cancer
A Phase II Trial of Adjuvant Paclitaxel and Trastuzumab for Node-Negative HER2-Positive Breast Cancer
Status: Enrolling
Updated:  1/30/2018
Dana-Farber at Faulkner Hospital
mi
from
Boston, MA
Adjuvant Paclitaxel and Trastuzumab for Node-Negative HER2-Positive Breast Cancer
A Phase II Trial of Adjuvant Paclitaxel and Trastuzumab for Node-Negative HER2-Positive Breast Cancer
Status: Enrolling
Updated: 1/30/2018
Dana-Farber at Faulkner Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Adjuvant Paclitaxel and Trastuzumab for Node-Negative HER2-Positive Breast Cancer
A Phase II Trial of Adjuvant Paclitaxel and Trastuzumab for Node-Negative HER2-Positive Breast Cancer
Status: Enrolling
Updated:  1/30/2018
Dana-Farber Cancer Institute
mi
from
Boston, MA
Adjuvant Paclitaxel and Trastuzumab for Node-Negative HER2-Positive Breast Cancer
A Phase II Trial of Adjuvant Paclitaxel and Trastuzumab for Node-Negative HER2-Positive Breast Cancer
Status: Enrolling
Updated: 1/30/2018
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
Adjuvant Paclitaxel and Trastuzumab for Node-Negative HER2-Positive Breast Cancer
A Phase II Trial of Adjuvant Paclitaxel and Trastuzumab for Node-Negative HER2-Positive Breast Cancer
Status: Enrolling
Updated:  1/30/2018
Cape Cod Healthcare
mi
from
Hyannis, MA
Adjuvant Paclitaxel and Trastuzumab for Node-Negative HER2-Positive Breast Cancer
A Phase II Trial of Adjuvant Paclitaxel and Trastuzumab for Node-Negative HER2-Positive Breast Cancer
Status: Enrolling
Updated: 1/30/2018
Cape Cod Healthcare
mi
from
Hyannis, MA
Click here to add this to my saved trials
Adjuvant Paclitaxel and Trastuzumab for Node-Negative HER2-Positive Breast Cancer
A Phase II Trial of Adjuvant Paclitaxel and Trastuzumab for Node-Negative HER2-Positive Breast Cancer
Status: Enrolling
Updated:  1/30/2018
Lowelll General Hospital
mi
from
Lowell, MA
Adjuvant Paclitaxel and Trastuzumab for Node-Negative HER2-Positive Breast Cancer
A Phase II Trial of Adjuvant Paclitaxel and Trastuzumab for Node-Negative HER2-Positive Breast Cancer
Status: Enrolling
Updated: 1/30/2018
Lowelll General Hospital
mi
from
Lowell, MA
Click here to add this to my saved trials
Adjuvant Paclitaxel and Trastuzumab for Node-Negative HER2-Positive Breast Cancer
A Phase II Trial of Adjuvant Paclitaxel and Trastuzumab for Node-Negative HER2-Positive Breast Cancer
Status: Enrolling
Updated:  1/30/2018
North Shore Medical Center
mi
from
Peabody, MA
Adjuvant Paclitaxel and Trastuzumab for Node-Negative HER2-Positive Breast Cancer
A Phase II Trial of Adjuvant Paclitaxel and Trastuzumab for Node-Negative HER2-Positive Breast Cancer
Status: Enrolling
Updated: 1/30/2018
North Shore Medical Center
mi
from
Peabody, MA
Click here to add this to my saved trials
Adjuvant Paclitaxel and Trastuzumab for Node-Negative HER2-Positive Breast Cancer
A Phase II Trial of Adjuvant Paclitaxel and Trastuzumab for Node-Negative HER2-Positive Breast Cancer
Status: Enrolling
Updated:  1/30/2018
Washington University
mi
from
Saint Louis, MO
Adjuvant Paclitaxel and Trastuzumab for Node-Negative HER2-Positive Breast Cancer
A Phase II Trial of Adjuvant Paclitaxel and Trastuzumab for Node-Negative HER2-Positive Breast Cancer
Status: Enrolling
Updated: 1/30/2018
Washington University
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Adjuvant Paclitaxel and Trastuzumab for Node-Negative HER2-Positive Breast Cancer
A Phase II Trial of Adjuvant Paclitaxel and Trastuzumab for Node-Negative HER2-Positive Breast Cancer
Status: Enrolling
Updated:  1/30/2018
North Shore-LIJ Health System Monter Cancer Center
mi
from
Lake Success, NY
Adjuvant Paclitaxel and Trastuzumab for Node-Negative HER2-Positive Breast Cancer
A Phase II Trial of Adjuvant Paclitaxel and Trastuzumab for Node-Negative HER2-Positive Breast Cancer
Status: Enrolling
Updated: 1/30/2018
North Shore-LIJ Health System Monter Cancer Center
mi
from
Lake Success, NY
Click here to add this to my saved trials
Adjuvant Paclitaxel and Trastuzumab for Node-Negative HER2-Positive Breast Cancer
A Phase II Trial of Adjuvant Paclitaxel and Trastuzumab for Node-Negative HER2-Positive Breast Cancer
Status: Enrolling
Updated:  1/30/2018
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Adjuvant Paclitaxel and Trastuzumab for Node-Negative HER2-Positive Breast Cancer
A Phase II Trial of Adjuvant Paclitaxel and Trastuzumab for Node-Negative HER2-Positive Breast Cancer
Status: Enrolling
Updated: 1/30/2018
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Adjuvant Paclitaxel and Trastuzumab for Node-Negative HER2-Positive Breast Cancer
A Phase II Trial of Adjuvant Paclitaxel and Trastuzumab for Node-Negative HER2-Positive Breast Cancer
Status: Enrolling
Updated:  1/30/2018
Weill-Cornell Medical College
mi
from
New York, NY
Adjuvant Paclitaxel and Trastuzumab for Node-Negative HER2-Positive Breast Cancer
A Phase II Trial of Adjuvant Paclitaxel and Trastuzumab for Node-Negative HER2-Positive Breast Cancer
Status: Enrolling
Updated: 1/30/2018
Weill-Cornell Medical College
mi
from
New York, NY
Click here to add this to my saved trials
Adjuvant Paclitaxel and Trastuzumab for Node-Negative HER2-Positive Breast Cancer
A Phase II Trial of Adjuvant Paclitaxel and Trastuzumab for Node-Negative HER2-Positive Breast Cancer
Status: Enrolling
Updated:  1/30/2018
University of North Carolina at Chapel Hill
mi
from
Chapel Hill, NC
Adjuvant Paclitaxel and Trastuzumab for Node-Negative HER2-Positive Breast Cancer
A Phase II Trial of Adjuvant Paclitaxel and Trastuzumab for Node-Negative HER2-Positive Breast Cancer
Status: Enrolling
Updated: 1/30/2018
University of North Carolina at Chapel Hill
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Adjuvant Paclitaxel and Trastuzumab for Node-Negative HER2-Positive Breast Cancer
A Phase II Trial of Adjuvant Paclitaxel and Trastuzumab for Node-Negative HER2-Positive Breast Cancer
Status: Enrolling
Updated:  1/30/2018
Duke Comprehensive Cancer Center
mi
from
Durham, NC
Adjuvant Paclitaxel and Trastuzumab for Node-Negative HER2-Positive Breast Cancer
A Phase II Trial of Adjuvant Paclitaxel and Trastuzumab for Node-Negative HER2-Positive Breast Cancer
Status: Enrolling
Updated: 1/30/2018
Duke Comprehensive Cancer Center
mi
from
Durham, NC
Click here to add this to my saved trials
Adjuvant Paclitaxel and Trastuzumab for Node-Negative HER2-Positive Breast Cancer
A Phase II Trial of Adjuvant Paclitaxel and Trastuzumab for Node-Negative HER2-Positive Breast Cancer
Status: Enrolling
Updated:  1/30/2018
Case Western University
mi
from
Cleveland, OH
Adjuvant Paclitaxel and Trastuzumab for Node-Negative HER2-Positive Breast Cancer
A Phase II Trial of Adjuvant Paclitaxel and Trastuzumab for Node-Negative HER2-Positive Breast Cancer
Status: Enrolling
Updated: 1/30/2018
Case Western University
mi
from
Cleveland, OH
Click here to add this to my saved trials
Adjuvant Paclitaxel and Trastuzumab for Node-Negative HER2-Positive Breast Cancer
A Phase II Trial of Adjuvant Paclitaxel and Trastuzumab for Node-Negative HER2-Positive Breast Cancer
Status: Enrolling
Updated:  1/30/2018
Tennesse Oncology, PLLC, Site # 076
mi
from
Nashville, TN
Adjuvant Paclitaxel and Trastuzumab for Node-Negative HER2-Positive Breast Cancer
A Phase II Trial of Adjuvant Paclitaxel and Trastuzumab for Node-Negative HER2-Positive Breast Cancer
Status: Enrolling
Updated: 1/30/2018
Tennesse Oncology, PLLC, Site # 076
mi
from
Nashville, TN
Click here to add this to my saved trials
Adjuvant Paclitaxel and Trastuzumab for Node-Negative HER2-Positive Breast Cancer
A Phase II Trial of Adjuvant Paclitaxel and Trastuzumab for Node-Negative HER2-Positive Breast Cancer
Status: Enrolling
Updated:  1/30/2018
The University of Vermont Cancer Center
mi
from
Burlington, VT
Adjuvant Paclitaxel and Trastuzumab for Node-Negative HER2-Positive Breast Cancer
A Phase II Trial of Adjuvant Paclitaxel and Trastuzumab for Node-Negative HER2-Positive Breast Cancer
Status: Enrolling
Updated: 1/30/2018
The University of Vermont Cancer Center
mi
from
Burlington, VT
Click here to add this to my saved trials
Neoadjuvant Propanolol in Breast Cancer
Pilot "Window of Opportunity" Neoadjuvant Study of Propranolol in Breast Cancer
Status: Enrolling
Updated:  1/31/2018
Texas Tech University HSC
mi
from
El Paso, TX
Neoadjuvant Propanolol in Breast Cancer
Pilot "Window of Opportunity" Neoadjuvant Study of Propranolol in Breast Cancer
Status: Enrolling
Updated: 1/31/2018
Texas Tech University HSC
mi
from
El Paso, TX
Click here to add this to my saved trials
Intraoperative Imaging of Breast Cancer With Indocyanine Green
A Phase 0/1, Open-Label, Single Center Study of the Imaging Potential of Indocyanine Green in Subject Undergoing Breast Cancer Surgery
Status: Enrolling
Updated:  2/1/2018
Hospital of the University of Pennsylvania
mi
from
Philadelphia, PA
Intraoperative Imaging of Breast Cancer With Indocyanine Green
A Phase 0/1, Open-Label, Single Center Study of the Imaging Potential of Indocyanine Green in Subject Undergoing Breast Cancer Surgery
Status: Enrolling
Updated: 2/1/2018
Hospital of the University of Pennsylvania
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Study of Prone Accelerated Breast And Nodal IMRT
PHASE I - II STUDY OF PRONE ACCELERATED BREAST AND NODAL IMRT(Intensity-Modulated Radiation Therapy)
Status: Enrolling
Updated:  2/1/2018
Laura and Issac Perlmutter Cancer Center
mi
from
New York, NY
Study of Prone Accelerated Breast And Nodal IMRT
PHASE I - II STUDY OF PRONE ACCELERATED BREAST AND NODAL IMRT(Intensity-Modulated Radiation Therapy)
Status: Enrolling
Updated: 2/1/2018
Laura and Issac Perlmutter Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Monitoring and Predicting Breast Cancer Neoadjuvant Chemotherapy Response Using Diffuse Optical Spectroscopic Imaging
Monitoring and Predicting Breast Cancer Neoadjuvant Chemotherapy Response Using Diffuse Optical Spectroscopic Imaging
Status: Enrolling
Updated:  2/2/2018
Beckman Laser Institute
mi
from
Irvine, CA
Monitoring and Predicting Breast Cancer Neoadjuvant Chemotherapy Response Using Diffuse Optical Spectroscopic Imaging
Monitoring and Predicting Breast Cancer Neoadjuvant Chemotherapy Response Using Diffuse Optical Spectroscopic Imaging
Status: Enrolling
Updated: 2/2/2018
Beckman Laser Institute
mi
from
Irvine, CA
Click here to add this to my saved trials
Prone Breath Hold Technique to Decrease Cardiac and Pulmonary Doses in Women Receiving Left Breast Radiotherapy
Pilot Study For Prone Breath Hold Technique to Decrease Cardiac and Pulmonary Doses in Women Receiving Left Breast Radiotherapy
Status: Enrolling
Updated:  2/2/2018
Radiation Oncology Department at the University of Arizona Heath Network
mi
from
Tucson, AZ
Prone Breath Hold Technique to Decrease Cardiac and Pulmonary Doses in Women Receiving Left Breast Radiotherapy
Pilot Study For Prone Breath Hold Technique to Decrease Cardiac and Pulmonary Doses in Women Receiving Left Breast Radiotherapy
Status: Enrolling
Updated: 2/2/2018
Radiation Oncology Department at the University of Arizona Heath Network
mi
from
Tucson, AZ
Click here to add this to my saved trials
An Investigation of Chemotherapy Induced Cognitive Impairments in Breast Cancer Survivors
An Investigation of Chemotherapy Induced Cognitive Impairments in Breast Cancer
Status: Enrolling
Updated:  2/2/2018
NYU Perlmutter Cancer Center
mi
from
New York, NY
An Investigation of Chemotherapy Induced Cognitive Impairments in Breast Cancer Survivors
An Investigation of Chemotherapy Induced Cognitive Impairments in Breast Cancer
Status: Enrolling
Updated: 2/2/2018
NYU Perlmutter Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Proactive Psychiatry Consultation for Patients With Cancer and Severe Mental Illness
Proactive Psychiatry Consultation for Patients With Cancer and Severe Mental Illness
Status: Enrolling
Updated:  2/2/2018
Massachusetts General Hospital
mi
from
Boston, MA
Proactive Psychiatry Consultation for Patients With Cancer and Severe Mental Illness
Proactive Psychiatry Consultation for Patients With Cancer and Severe Mental Illness
Status: Enrolling
Updated: 2/2/2018
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Abraxane and Lapatinib in Treating Patients With Stage I, Stage II, or Stage III Breast Cancer
Pilot Neoadjuvant Trial in Breast Cancer With Combination of ABI-007 (Abraxane) and GW572016 (Lapatinib)
Status: Enrolling
Updated:  2/2/2018
Northwestern University, Northwestern Medical Faculty Foundation
mi
from
Chicago, IL
Abraxane and Lapatinib in Treating Patients With Stage I, Stage II, or Stage III Breast Cancer
Pilot Neoadjuvant Trial in Breast Cancer With Combination of ABI-007 (Abraxane) and GW572016 (Lapatinib)
Status: Enrolling
Updated: 2/2/2018
Northwestern University, Northwestern Medical Faculty Foundation
mi
from
Chicago, IL
Click here to add this to my saved trials
Abraxane and Lapatinib in Treating Patients With Stage I, Stage II, or Stage III Breast Cancer
Pilot Neoadjuvant Trial in Breast Cancer With Combination of ABI-007 (Abraxane) and GW572016 (Lapatinib)
Status: Enrolling
Updated:  2/2/2018
Hematology-Oncology Associates of Illinois
mi
from
Chicago, IL
Abraxane and Lapatinib in Treating Patients With Stage I, Stage II, or Stage III Breast Cancer
Pilot Neoadjuvant Trial in Breast Cancer With Combination of ABI-007 (Abraxane) and GW572016 (Lapatinib)
Status: Enrolling
Updated: 2/2/2018
Hematology-Oncology Associates of Illinois
mi
from
Chicago, IL
Click here to add this to my saved trials
Abraxane and Lapatinib in Treating Patients With Stage I, Stage II, or Stage III Breast Cancer
Pilot Neoadjuvant Trial in Breast Cancer With Combination of ABI-007 (Abraxane) and GW572016 (Lapatinib)
Status: Enrolling
Updated:  2/2/2018
Midwest Center for Hematology/Oncology
mi
from
Joliet, IL
Abraxane and Lapatinib in Treating Patients With Stage I, Stage II, or Stage III Breast Cancer
Pilot Neoadjuvant Trial in Breast Cancer With Combination of ABI-007 (Abraxane) and GW572016 (Lapatinib)
Status: Enrolling
Updated: 2/2/2018
Midwest Center for Hematology/Oncology
mi
from
Joliet, IL
Click here to add this to my saved trials
Abraxane and Lapatinib in Treating Patients With Stage I, Stage II, or Stage III Breast Cancer
Pilot Neoadjuvant Trial in Breast Cancer With Combination of ABI-007 (Abraxane) and GW572016 (Lapatinib)
Status: Enrolling
Updated:  2/2/2018
Saint James Hospital and Health Centers Comprehensive Cancer Institute - Olympia Fields
mi
from
Olympia Fields, IL
Abraxane and Lapatinib in Treating Patients With Stage I, Stage II, or Stage III Breast Cancer
Pilot Neoadjuvant Trial in Breast Cancer With Combination of ABI-007 (Abraxane) and GW572016 (Lapatinib)
Status: Enrolling
Updated: 2/2/2018
Saint James Hospital and Health Centers Comprehensive Cancer Institute - Olympia Fields
mi
from
Olympia Fields, IL
Click here to add this to my saved trials
Abraxane and Lapatinib in Treating Patients With Stage I, Stage II, or Stage III Breast Cancer
Pilot Neoadjuvant Trial in Breast Cancer With Combination of ABI-007 (Abraxane) and GW572016 (Lapatinib)
Status: Enrolling
Updated:  2/2/2018
Joe Arrington Cancer Research and Treatment Center
mi
from
Lubbock, TX
Abraxane and Lapatinib in Treating Patients With Stage I, Stage II, or Stage III Breast Cancer
Pilot Neoadjuvant Trial in Breast Cancer With Combination of ABI-007 (Abraxane) and GW572016 (Lapatinib)
Status: Enrolling
Updated: 2/2/2018
Joe Arrington Cancer Research and Treatment Center
mi
from
Lubbock, TX
Click here to add this to my saved trials
Studying the Effect of Freeze-Dried Table Grape Powder on Blood Estrogen Levels in Postmenopausal Women
Evaluation of the Aromatase Inhibition Potential of Standardized Grape Extract
Status: Enrolling
Updated:  2/5/2018
The Mayo Clinic
mi
from
Rochester, MN
Studying the Effect of Freeze-Dried Table Grape Powder on Blood Estrogen Levels in Postmenopausal Women
Evaluation of the Aromatase Inhibition Potential of Standardized Grape Extract
Status: Enrolling
Updated: 2/5/2018
The Mayo Clinic
mi
from
Rochester, MN
Click here to add this to my saved trials
Longitudinal Assessment of Arthralgia and Related Symptoms in Breast Cancer Patients Receiving Aromatase Inhibitors
Longitudinal Assessment of Arthralgia and Related Symptoms in Breast Cancer Patients Receiving Aromatase Inhibitors
Status: Enrolling
Updated:  2/5/2018
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Longitudinal Assessment of Arthralgia and Related Symptoms in Breast Cancer Patients Receiving Aromatase Inhibitors
Longitudinal Assessment of Arthralgia and Related Symptoms in Breast Cancer Patients Receiving Aromatase Inhibitors
Status: Enrolling
Updated: 2/5/2018
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
QOL Assessment in Breast Cancer Patients With Radiation-Induced Telangiectasias Treated With the Pulsed Dye Laser
Quality of Life Assessment in Breast Cancer Patients With Radiation-Induced Telangiectasias Treated With the Pulsed Dye Laser
Status: Enrolling
Updated:  2/5/2018
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
QOL Assessment in Breast Cancer Patients With Radiation-Induced Telangiectasias Treated With the Pulsed Dye Laser
Quality of Life Assessment in Breast Cancer Patients With Radiation-Induced Telangiectasias Treated With the Pulsed Dye Laser
Status: Enrolling
Updated: 2/5/2018
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
1303GCC: Trastuzmab & Pertuzumab With Hormonal Therapy or Chemotherapy in Women Aged 60 and Over.
1303GCC: Phase II Study of Trastuzumab and Pertuzumab Alone and in Combination With Hormonal Therapy or Chemotherapy in Women Aged 60 and Over With HER2/Neu Overexpressed Locally Advanced and/or Metastatic Breast Carcinoma
Status: Enrolling
Updated:  2/5/2018
University of Maryland/Marlene and Stewart Greenebaum Cancer Center
mi
from
Baltimore, MD
1303GCC: Trastuzmab & Pertuzumab With Hormonal Therapy or Chemotherapy in Women Aged 60 and Over.
1303GCC: Phase II Study of Trastuzumab and Pertuzumab Alone and in Combination With Hormonal Therapy or Chemotherapy in Women Aged 60 and Over With HER2/Neu Overexpressed Locally Advanced and/or Metastatic Breast Carcinoma
Status: Enrolling
Updated: 2/5/2018
University of Maryland/Marlene and Stewart Greenebaum Cancer Center
mi
from
Baltimore, MD
Click here to add this to my saved trials
Breast Cancer Genome Guided Therapy Study (BEAUTY)
Breast Cancer Genome Guided Therapy Study (BEAUTY)
Status: Enrolling
Updated:  2/5/2018
Mayo Clinic Campus in Arizona
mi
from
Scottsdale, AZ
Breast Cancer Genome Guided Therapy Study (BEAUTY)
Breast Cancer Genome Guided Therapy Study (BEAUTY)
Status: Enrolling
Updated: 2/5/2018
Mayo Clinic Campus in Arizona
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
Breast Cancer Genome Guided Therapy Study (BEAUTY)
Breast Cancer Genome Guided Therapy Study (BEAUTY)
Status: Enrolling
Updated:  2/5/2018
The Mayo Clinic
mi
from
Rochester, MN
Breast Cancer Genome Guided Therapy Study (BEAUTY)
Breast Cancer Genome Guided Therapy Study (BEAUTY)
Status: Enrolling
Updated: 2/5/2018
The Mayo Clinic
mi
from
Rochester, MN
Click here to add this to my saved trials
Real Time Optical Coherence Tomography (OCT) of Human Tissue
Real Time Optical Coherence Tomography (OCT) of Human Tissue
Status: Enrolling
Updated:  2/6/2018
Carle Foundation Hospital
mi
from
Urbana, IL
Real Time Optical Coherence Tomography (OCT) of Human Tissue
Real Time Optical Coherence Tomography (OCT) of Human Tissue
Status: Enrolling
Updated: 2/6/2018
Carle Foundation Hospital
mi
from
Urbana, IL
Click here to add this to my saved trials
Educational Counseling in Improving Communication and Quality of Life in Spouses and Breast Cancer Patients
Psychoeducation for Spouses/Partners of Women With Breast Cancer
Status: Enrolling
Updated:  2/6/2018
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
mi
from
Seattle, WA
Educational Counseling in Improving Communication and Quality of Life in Spouses and Breast Cancer Patients
Psychoeducation for Spouses/Partners of Women With Breast Cancer
Status: Enrolling
Updated: 2/6/2018
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
mi
from
Seattle, WA
Click here to add this to my saved trials
Computed Optical Margin Assessment for Breast Cancer Surgery, Phase I (Part B)
Computed Optical Margin Assessment for Breast Cancer Surgery, Phase I (Part B)
Status: Enrolling
Updated:  2/6/2018
Johns Hopkins Hospital
mi
from
Baltimore, MD
Computed Optical Margin Assessment for Breast Cancer Surgery, Phase I (Part B)
Computed Optical Margin Assessment for Breast Cancer Surgery, Phase I (Part B)
Status: Enrolling
Updated: 2/6/2018
Johns Hopkins Hospital
mi
from
Baltimore, MD
Click here to add this to my saved trials
Valproic Acid in Combination With FEC100 for Primary Therapy in Patients With Breast Cancer
A Phase II Study of Valproic Acid in Combination With FEC100 for Primary Therapy in Patients With Locally Advanced or Primary Metastatic Breast Cancer
Status: Enrolling
Updated:  2/8/2018
University of California at San Francisco
mi
from
San Francisco, CA
Valproic Acid in Combination With FEC100 for Primary Therapy in Patients With Breast Cancer
A Phase II Study of Valproic Acid in Combination With FEC100 for Primary Therapy in Patients With Locally Advanced or Primary Metastatic Breast Cancer
Status: Enrolling
Updated: 2/8/2018
University of California at San Francisco
mi
from
San Francisco, CA
Click here to add this to my saved trials
Naltrexone RCT for Treatment-Emergent Fatigue in Patients Receiving Radiation Therapy for Breast Cancer
Naltrexone Randomized Controlled Trial for Treatment-Emergent Fatigue in Patients Receiving Radiation Therapy for Breast Cancer
Status: Enrolling
Updated:  2/8/2018
Massachusetts General Hosptial
mi
from
Boston, MA
Naltrexone RCT for Treatment-Emergent Fatigue in Patients Receiving Radiation Therapy for Breast Cancer
Naltrexone Randomized Controlled Trial for Treatment-Emergent Fatigue in Patients Receiving Radiation Therapy for Breast Cancer
Status: Enrolling
Updated: 2/8/2018
Massachusetts General Hosptial
mi
from
Boston, MA
Click here to add this to my saved trials
Naltrexone RCT for Treatment-Emergent Fatigue in Patients Receiving Radiation Therapy for Breast Cancer
Naltrexone Randomized Controlled Trial for Treatment-Emergent Fatigue in Patients Receiving Radiation Therapy for Breast Cancer
Status: Enrolling
Updated:  2/8/2018
Dana-Farber Cancer Institute
mi
from
Boston, MA
Naltrexone RCT for Treatment-Emergent Fatigue in Patients Receiving Radiation Therapy for Breast Cancer
Naltrexone Randomized Controlled Trial for Treatment-Emergent Fatigue in Patients Receiving Radiation Therapy for Breast Cancer
Status: Enrolling
Updated: 2/8/2018
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
Niraparib in Combination With Pembrolizumab in Patients With Triple-negative Breast Cancer or Ovarian Cancer
Phase 1/2 Clinical Study of Niraparib in Combination With Pembrolizumab (MK-3475) in Patients With Advanced or Metastatic Triple-Negative Breast Cancer and in Patients With Recurrent Ovarian Cancer
Status: Enrolling
Updated:  2/8/2018
Clinical Research Facility
mi
from
Scottsdale, AZ
Niraparib in Combination With Pembrolizumab in Patients With Triple-negative Breast Cancer or Ovarian Cancer
Phase 1/2 Clinical Study of Niraparib in Combination With Pembrolizumab (MK-3475) in Patients With Advanced or Metastatic Triple-Negative Breast Cancer and in Patients With Recurrent Ovarian Cancer
Status: Enrolling
Updated: 2/8/2018
Clinical Research Facility
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
Niraparib in Combination With Pembrolizumab in Patients With Triple-negative Breast Cancer or Ovarian Cancer
Phase 1/2 Clinical Study of Niraparib in Combination With Pembrolizumab (MK-3475) in Patients With Advanced or Metastatic Triple-Negative Breast Cancer and in Patients With Recurrent Ovarian Cancer
Status: Enrolling
Updated:  2/8/2018
Clinical Research Facility
mi
from
Detroit, MI
Niraparib in Combination With Pembrolizumab in Patients With Triple-negative Breast Cancer or Ovarian Cancer
Phase 1/2 Clinical Study of Niraparib in Combination With Pembrolizumab (MK-3475) in Patients With Advanced or Metastatic Triple-Negative Breast Cancer and in Patients With Recurrent Ovarian Cancer
Status: Enrolling
Updated: 2/8/2018
Clinical Research Facility
mi
from
Detroit, MI
Click here to add this to my saved trials
Niraparib in Combination With Pembrolizumab in Patients With Triple-negative Breast Cancer or Ovarian Cancer
Phase 1/2 Clinical Study of Niraparib in Combination With Pembrolizumab (MK-3475) in Patients With Advanced or Metastatic Triple-Negative Breast Cancer and in Patients With Recurrent Ovarian Cancer
Status: Enrolling
Updated:  2/8/2018
Clinical Research Facility
mi
from
Oklahoma City, OK
Niraparib in Combination With Pembrolizumab in Patients With Triple-negative Breast Cancer or Ovarian Cancer
Phase 1/2 Clinical Study of Niraparib in Combination With Pembrolizumab (MK-3475) in Patients With Advanced or Metastatic Triple-Negative Breast Cancer and in Patients With Recurrent Ovarian Cancer
Status: Enrolling
Updated: 2/8/2018
Clinical Research Facility
mi
from
Oklahoma City, OK
Click here to add this to my saved trials